Growth-Hormone & Body-Composition Research
CJC-1295 + DAC 5mg
CJC-1295 + DAC 5mg
Extended GHRH signalling for longer-window endocrine research.
A long-acting GHRH analogue studied for sustained growth-hormone and IGF-1 signalling in endocrine research.
- Documentation
- Check batch record
- Availability
- In stock
For qualified laboratory research only · Not for human or veterinary use
Why researchers choose it
CJC-1295 with drug-affinity-complex modification was designed for extended exposure, enabling study of sustained GH and IGF-1 axis activation rather than a brief GHRH pulse.
Research focus
- Long-acting GHRH analogue research
- Growth-hormone and IGF-1 signalling
- Extended endocrine-response windows
Evidence snapshot
Short controlled human studies recorded sustained GH and IGF-1 biomarker changes. They do not establish muscle gain, fat loss, recovery outcomes or long-term safety.
Best suited to
For endocrine-signalling research with timed biomarker and exposure measurements.
Research focus describes published study domains, not a guaranteed outcome. No human or veterinary dosing, reconstitution or administration instructions are supplied.
Related research compounds
GH & Body Composition10mg
A selective ghrelin-receptor agonist studied for controlled growth-hormone release and secretagogue pharmacology.
GH & Body Composition10mg
A GHRF analogue studied across growth-hormone signalling, IGF-1 response and visceral-adipose biology.